Alpha Lipoic Acid: Benefits, Dosage and What the Research Actually Shows
Alpha lipoic acid (ALA) has a property that no other antioxidant in your body fully replicates: it's both water-soluble and fat-soluble. Most antioxidants work in only one of those environments. Vitamin C stays in aqueous compartments. Vitamin E works in lipid membranes. ALA can operate in both, and it also regenerates several other antioxidants — including vitamins C and E and glutathione — back to their active forms. That's why it's sometimes called a "universal antioxidant."
But what does that actually mean clinically? Here's where the evidence is strong, where it's mixed, and what to know about dosage and safety.
Please note: This article is for informational purposes only. Alpha lipoic acid can lower blood glucose and interact with diabetes medications. If you have diabetes or take blood sugar-lowering drugs, consult your prescriber before adding ALA to your routine. Pregnant and breastfeeding women should also consult a healthcare provider before use.
What Alpha Lipoic Acid Does in the Body
ALA exists in two forms: the R-form (naturally occurring, more biologically active) and the S-form (produced synthetically). Most supplements contain a racemic mixture of both. The R-form is more potent, and some premium formulations specify "R-ALA" or "R(+)-alpha lipoic acid."
Its antioxidant functions include directly scavenging reactive oxygen species (ROS), chelating metal ions (particularly copper and iron) that catalyze free radical production, and regenerating glutathione, vitamins C and E, and coenzyme Q10. This recycling capacity is what distinguishes ALA from most antioxidants, which are single-use and become inert after neutralizing a free radical.
ALA also activates AMPK (the same energy-sensing enzyme activated by metformin and berberine), improves mitochondrial function, and reduces inflammatory signaling via NF-κB inhibition. These multiple overlapping mechanisms explain its usefulness in metabolic and neurological conditions.
The Strongest Evidence: Diabetic Neuropathy
ALA has more robust human clinical trial evidence in any supplement category than almost any non-pharmaceutical compound. The evidence is most compelling for diabetic peripheral neuropathy — nerve damage in the hands and feet caused by chronic elevated blood glucose and the resulting oxidative stress.
The landmark trial was the ALADIN study — Alpha-Lipoic Acid in Diabetic Neuropathy — by Ziegler et al. published in Diabetologia in 1995 (428 citations). In this multicenter, randomized, double-blind, placebo-controlled trial, 328 non-insulin-dependent diabetic patients with symptomatic peripheral neuropathy received intravenous ALA at three doses (100, 600, or 1,200 mg) or placebo daily for 3 weeks. The 600 mg ALA group achieved a 63.5% reduction in the Total Symptom Score (stabbing pain, burning, paresthesias, numbness) versus 38.4% in the placebo group (p<0.001). Response rates were 82.5% for 600 mg versus 57.6% for placebo.
For oral ALA, the SYDNEY 2 trial (Ziegler et al., 2006, 500 citations) tested once-daily oral doses of 600 mg, 1,200 mg, and 1,800 mg versus placebo in 181 diabetic patients with polyneuropathy over 5 weeks. All three ALA doses significantly reduced neuropathic symptoms compared to placebo (approximately 50% reduction vs 32%). The 600 mg once-daily dose showed the best risk-to-benefit ratio — the higher doses added more adverse events (nausea, vomiting) without proportionally better symptom control.
A 2023 meta-analysis by Hsieh et al. in Nutrients, covering 10 RCTs with 1,242 patients, confirmed that oral ALA treatment produced favorable results for Total Symptom Score and overall neuropathy severity in diabetic sensorimotor peripheral neuropathy, with a dose-related trend observed. The evidence for symptom reduction is consistent across multiple independent trials.
A longer-term 4-year RCT (Ziegler et al., 2011, 275 citations) tested oral ALA 600 mg daily in 460 patients with mild-to-moderate diabetic neuropathy. The primary composite endpoint did not reach statistical significance, but secondary outcomes showed ALA produced clinically meaningful improvement in neuropathic impairments — more patients improved and fewer progressed compared to placebo on neuropathy scales.
The bottom line on diabetic neuropathy: oral ALA at 600 mg per day has consistent evidence for reducing neuropathic symptoms. The European Federation of Neurological Societies includes it in treatment guidelines for symptomatic diabetic neuropathy as a recognized option.
Blood Sugar and Insulin Sensitivity
ALA improves insulin-mediated glucose uptake in skeletal muscle by activating AMPK and increasing glucose transporter (GLUT4) translocation to the cell membrane. Several clinical trials have shown reductions in fasting blood glucose and HbA1c with ALA supplementation in diabetic or prediabetic populations.
The effects are meaningful but not as large as pharmaceutical agents. ALA works better as an adjunct to primary diabetes management than as a standalone blood sugar treatment. For people with prediabetes or borderline insulin resistance who are focused on lifestyle and nutritional optimization, ALA at 600–1,200 mg per day is a well-reasoned addition given its dual antioxidant and metabolic mechanisms.
Other Areas With Emerging Evidence
Weight management. Several trials suggest ALA supplementation (1,200–1,800 mg/day) modestly reduces body weight and BMI in overweight individuals, potentially through appetite-regulating effects in the hypothalamus and increased energy expenditure. Effects are small — typically 1–2 kg over 20 weeks — and most pronounced in women and those with higher baseline BMI.
Cognitive function and neurological conditions. ALA crosses the blood-brain barrier and reduces oxidative stress in neural tissue. Preliminary clinical evidence exists for modest cognitive benefits in early Alzheimer's disease and vascular dementia when combined with omega-3 fatty acids. This remains an active research area without definitive conclusions.
Inflammation and cardiovascular risk markers. Meta-analyses show ALA supplementation consistently reduces C-reactive protein (CRP), a key inflammatory marker, and may modestly lower LDL cholesterol and triglycerides. These effects are consistent with its antioxidant and AMPK-activating mechanisms.
Forms and Dosage
Standard ALA (racemic mixture): 300–600 mg once daily is the best-studied dose range for neuropathy and metabolic benefits. The SYDNEY 2 trial established 600 mg once daily as optimal for symptom/side effect balance.
R-ALA (natural isomer only): Generally dosed lower, around 100–300 mg per day, because of higher biological potency per milligram. R-ALA is less stable than racemic ALA and can degrade faster, so storage in cool, dark conditions matters more.
Stabilized R-ALA (Na-RALA, potassium RALA): Sodium or potassium salt formulations improve stability. Worth seeking out if you're specifically paying for the R-form.
ALA is best taken 30–60 minutes before meals on an empty stomach for better absorption. Food, particularly high-fat meals, can reduce ALA bioavailability.
Safety and Interactions
ALA is generally well-tolerated at clinical doses. The most common side effects at higher doses (1,200–1,800 mg) are nausea, vomiting, and vertigo — dose-dependent effects that are rarely seen at 600 mg.
The most important interaction: blood glucose lowering. ALA can meaningfully lower blood sugar, which creates hypoglycemia risk if combined with insulin, metformin, sulfonylureas, or other blood glucose-lowering drugs without dose adjustment. This is not a theoretical concern — it's documented in clinical experience. If you're on any diabetic medications, discuss ALA with your prescriber before starting.
ALA depletes biotin (vitamin B7) with long-term high-dose use by competing for the same intestinal transporter. People taking ALA for extended periods at doses above 600 mg may benefit from supplementing 1–2 mg of biotin daily to prevent depletion.